Adage Capital Partners’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
Adage Capital Partners's TSHA Position: Q3 2026 in Review
Adage Capital Partners sold out of Taysha Gene Therapies (TSHA) in Q3 2026, closing a stake of 553,000 shares — an estimated $3.77M sold.
Adage Capital Partners first reported a position in TSHA in Q3 2023 and held it in 8 quarters. The position peaked at $11.2M in Q2 2025. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.
- Adage Capital Partners reported no remaining Taysha Gene Therapies position as of Q3 2026 after selling out during the quarter.
- Adage Capital Partners sold 553,000 Taysha Gene Therapies shares in Q3 2026, an estimated $3.77M.
- Adage Capital Partners first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 8 quarters.
- Adage Capital Partners's Taysha Gene Therapies position peaked at $11.2M in Q2 2025.
- 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.
Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.